No severe adverse reactions were reported. The only negative reactions were mild, most commonly pain at the injection site, which was experienced at about the same rate as seen with any flu vaccine.
In the trial, 1,614 participants over the age of 3 were inoculated. Blood samples were collected on the vaccination date, and then 14 and 21 days post vaccination date. The National Institute for the Control of Pharmaceutical and Biological Products (NICBPB), the central laboratory of the SFDA, completed the HI antibody tests on all blood samples.
Earlier, Sinovac said the trial would involve two inoculations and that it would have vaccine ready for sale in late September, after the trial was concluded and SFDA approval granted. With a single inoculation, the schedule may be moved forward.
